RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announce that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction. Based upon RadNet’s closing price on Monday, April 14, 2025, this represents a transaction value of approximately $103 million, or approximately $3.61 per share of iCAD common stock on a fully diluted basis.
Read the full article: RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer //
Source: https://www.globenewswire.com/news-release/2025/04/15/3062106/10985/en/RadNet-Inc-to-Acquire-iCAD-Inc-to-Accelerate-AI-Powered-Early-Detection-and-Diagnosis-of-Breast-Cancer.html